NCT01967160 is a clinical trial in Osteonecrosis of the Jaw, sponsored by Amgen.

Who is sponsoring NCT01967160?

NCT01967160 is sponsored by Amgen.

What condition does NCT01967160 study?

NCT01967160 studies Osteonecrosis of the Jaw, Infection Leading to Hospitalization.

Is NCT01967160 still recruiting?

NCT01967160 is currently completed. Last updated 22 June 2023.

Last reviewed 2023-06-22 · How we verify

NCT01967160

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Osteonecrosis of the Jaw (ONJ) and Infection Among Nordic Cancer Patients Treated With XGEVA™ or Zoledronic Acid

Completed Last updated 22 June 2023

What this trial tests

trial in Osteonecrosis of the Jaw in 2,560 participants. Completed in 5 August 2019.

Timeline

2 January 2012

Primary endpoint
5 August 2019

5 August 2019

Quick facts

Lead sponsor	Amgen
Status	Completed
Study type	OBSERVATIONAL
Enrollment	2,560
Start date	2 January 2012
Primary completion	5 August 2019
Estimated completion	5 August 2019

Conditions studied

Osteonecrosis of the Jaw — all drugs for Osteonecrosis of the Jaw →
Infection Leading to Hospitalization — all drugs for Infection Leading to Hospitalization →

Sponsor

Amgen — full company profile →

Who can join

Adults 18 to 99, any sex, with Osteonecrosis of the Jaw or Infection Leading to Hospitalization. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A non-interventional study to assess incident rates of Osteonecrosis of the Jaw and Infections leading to hospitalization in Cancer patients treated with XGEVA™ in Sweden, Denmark and Norway.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

Existing data sources for clinical epidemiology: Scandinavian Cohort for osteonecrosis of the jaw - work in progress and challenges.
Schiodt M, Larsson Wexell C, Herlofson BB, Giltvedt KM, et al · · 2015 · cited 13× · PMID 25657594 · DOI 10.2147/clep.s71796
Design and methods for a Scandinavian pharmacovigilance study of osteonecrosis of the jaw and serious infections among cancer patients treated with antiresorptive agents for the prevention of skeletal-related events.
Acquavella J, Ehrenstein V, Schiødt M, Heide-Jørgensen U, et al · · 2016 · cited 6× · PMID 27499646 · DOI 10.2147/clep.s107270
Outcomes of Clinical Trials on Osteonecrosis of the Jaw.
Wu BW, Lee KC, Halepas S, Karlis V. · · 2021 · PMID 34660159 · DOI 10.7759/cureus.17984

Verify or expand the search:

Other recruiting trials for Osteonecrosis of the Jaw

Currently open trials in the same condition.

NCT06457776 — Medication Related Osteonecrosis of the Jaws (MRONJ) in a Cohort of Patients Treated by Antiresorptive Drugs · recruiting

Other Amgen trials

Trials by the same sponsor.

NCT07223190 — A Study Evaluating Subcutaneous Versus Intravenous Blinatumomab in Newly Diagnosed Adults With B-cell Precursor Acute Ly · Phase 3 · not yet recruiting
NCT07493512 — Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer · Phase 1 · not yet recruiting
NCT07531095 — Study of Tarlatamab + ZL-1310 +/- Anti-programmed Death Ligand 1 (Anti-PD-L1) in Small Cell Lung Cancer (SCLC) · Phase 1 · not yet recruiting
NCT06987539 — A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Gen · Phase 2 · recruiting
NCT05909761 — Observational Safety Study in Women With Neuromyelitis Optica Spectrum Disorder (NMOSD) Exposed to UPLIZNA® During Pregn · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01967160 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Amgen
Last refreshed: 22 June 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01967160.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing